SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML)

NCT01261312 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

414

Enrollment

INDUSTRY

Sponsor class

Conditions

MDS
CMML
AML

Interventions

DRUG: Guadecitabine

Sponsor

Astex Pharmaceuticals, Inc.